This analysis demonstrates the role of biomarkers in risk stratification for prostate cancer, suggesting the need for prospective studies.
The extended immunohistochemical profile (AMACR, NKX3.1, Ki-67) provides valuable biological information correlated with tumor aggressiveness. Integrating these markers into the preoperative evaluation, along with standard histopathological evaluation and the peritumoral microenvironment, may contribute to a more accurate risk stratification. However, these findings are correlative, and their clinical applicability requires validation through further prospective studies.
No takes yet. Share an insight, caveat, or question.
Roşu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: